Publications by authors named "Marie Beylot-Barry"
Article Synopsis
- - The study investigates primary cutaneous marginal zone lymphoma (PCMZL) by analyzing recurrent cases to determine whether it's a reactive process or a true lymphoma, utilizing data from the French Study Group of Cutaneous Lymphoma (GFELC).
- - Methods included assessing histology, B-cell clonality, and immunophenotype of lesions, revealing that most initial cases were localized, with differences in recurrence times based on location, and certain clonal patterns were more prominent in local recurrences.
- - The findings suggest that assessing immunoglobulin phenotype, particularly IgM and IgD, may be critical for diagnosing PCMZL, as IgM-positive cases tend to lead to more aggressive transformation and poorer prognosis, indicating different biological
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study.
Joint Bone Spine
October 2024
Introduction: Immune checkpoint inhibitors-induced inflammatory arthritis (ICI-IA) affects about 5% of ICI recipients. We aimed (1) to characterize the resolution of ICI-IA during ICI treatment and after ICI discontinuation and (2) to assess how ICI-IA influences ICI management across time.
Methods: All ICI-treated patients referred to rheumatology at Bordeaux University Hospital were identified and patients with ICI-IA with a follow-up of≥6months after ICI-IA onset were included.
Article Synopsis
- The phase III KEYNOTE-913 study focused on assessing the effectiveness and safety of pembrolizumab as a first-line treatment for advanced Merkel cell carcinoma (MCC).
- Results indicated a 49% objective response rate among the 55 patients treated, with a median duration of response of 39.8 months and median overall survival of 24.3 months.
- The treatment showed manageable side effects, with 69% of patients experiencing any grade adverse events, but only 24% facing severe issues, highlighting pembrolizumab's potential in this patient group.
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
J Am Acad Dermatol
January 2025
Article Synopsis
- - The phase 2 EMPOWER-CSCC-1 study showed that cemiplimab is effective against advanced cutaneous squamous cell carcinoma (CSCC), specifically in metastatic and locally advanced cases.
- - The study involved different treatment groups receiving either weight-based or fixed-dose cemiplimab, with a significant overall response rate (ORR) of 47.2% after 42.5 months and noted long-duration responses.
- - While the findings are promising, the study's limitations include its nonrandomized design and the fact that the primary endpoint was not based on survival rates.
Background: Mycosis fungoides (MF) has usually an indolent course. However, some patients develop a more aggressive disease and few prognostic parameters have been identified. Isolated cases of pustular MF (pMF) suggest an unfavourable prognosis.
View Article and Find Full Text PDFImmune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation . While guidelines recommend discontinuing ICIs for grade 3 partial and all grade 4 irAEs, there is growing interest in rechallenging patients based on oncological outcomes, particularly for cardiovascular and neurological irAEs where data remains scarce . We retrospectively evaluated the safety of ICI rechallenge following grade 3-4 irAEs, specifically focusing on cardiovascular and neurological events, in patients discussed at our multidisciplinary immunotoxicity assessment board between 2019 and 2021.
View Article and Find Full Text PDFArticle Synopsis
- Sézary syndrome is a rare and deadly skin cancer, and this study looked into the survival rates and factors affecting outcomes, particularly focusing on the treatment mogamulizumab.
- *The research analyzed data from 339 patients diagnosed between 2000 and 2020 across Europe, highlighting that age over 80 and large-cell transformation worsened survival rates.
- *Results indicated that patients treated with mogamulizumab had significantly lower mortality rates, suggesting it is an effective treatment option for Sézary syndrome.
Background: Cutaneous adnexal carcinomas are a heterogeneous group of rare neoplasms. Surgical excision is the first-line treatment in localized stage. The use and effectiveness of radiotherapy have not been thoroughly evaluated in these neoplasms.
View Article and Find Full Text PDFPrimary cutaneous lymphomas (PCLs) are a heterogeneous group of lymphoproliferative disorders caused by the accumulation of neoplastic T or B lymphocytes in the skin. Sézary syndrome (SS) is an aggressive and rare form of cutaneous T cell lymphoma (CTCL) characterized by an erythroderma and the presence of atypical cerebriform T cells named Sézary cells in skin and blood. Most of the available treatments for SS are not curative, which means there is an urgent need for the development of novel efficient therapies.
View Article and Find Full Text PDFReal-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study.
Br J Dermatol
August 2024
Article Synopsis
- Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic skin cancers that require various treatment strategies; interferon-α (IFN-α) has been used for years, but only the pegylated form, PEG-IFN-α-2a, remains available, though not officially approved for these conditions.
- A study involving 105 patients across 10 countries assessed the effectiveness and safety of PEG-IFN-α-2a, focusing on the time to next treatment (TTNT) as a measure of its clinical benefit.
- Results showed a 53.3% overall response rate with better TTNT for patients receiving combination therapy (10.4 months) compared
Purpose: Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in white-skinned populations. There is little information on the epidemiology of cSCC, and even less on advanced cases (acSCC). Therefore, we analyzed acSCC patients to describe their characteristics, management, and outcomes over time.
View Article and Find Full Text PDFArticle Synopsis
- Cemiplimab (Libtayo) is an approved antibody used to treat advanced skin cancer (CSCC) in patients who can't undergo surgery or radiation, and it's typically given every three weeks.
- A study tested giving a higher dose (600 mg) every four weeks instead, involving 63 patients who were monitored for tumor response over 48 weeks.
- Results showed a 62% objective response rate with significant antitumor activity and manageable side effects like diarrhea and fatigue, suggesting this new dosing schedule could be effective but needs further data for comparison with the standard treatment.
Article Synopsis
- The Ritux 3 trial showed that rituximab is effective and safe as a first-line treatment for pemphigus, although long-term follow-up data was previously lacking.!* -
- This 7-year follow-up study evaluated the long-term outcomes for patients treated with rituximab alongside prednisone versus those treated with prednisone alone, focusing on disease-free survival and relapse rates.!* -
- Results indicated that 93% of patients in the rituximab group achieved complete remission without corticosteroids, showing significantly higher disease-free survival and lower relapse rates compared to the prednisone-only group.!*
Purpose: While several studies reported the influence of co-medications on immune checkpoint therapy and chemotherapy, it remains poorly studied with targeted therapy. Targeted therapies inhibiting BRAF and MEK had significantly improved management of advanced melanoma with BRAFV600 mutation over the last decade, we aimed to investigate the possible influence of co-mediations on the efficacy and toxicity of these targeted therapies (TT).
Methods: We conducted an observational study identifying patients with advanced melanoma treated with BRAF/MEK inhibitors between 2013 and 2020 in the Bordeaux University Hospital.
Objective: Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting. We aimed to assess the rate and clinical features associated with ICI-IA flare/recurrence on ICI rechallenge.
Methods: We conducted a multicentre observational study including cancer patients with ICI-IA who started a second course of ICI more than 3 months after ICI discontinuation in four French university hospitals.
Article Synopsis
- Aging is when our bodies slowly lose strength and abilities needed to stay alive and reproduce over time.!
- T-cells, a type of immune cell, change a lot as we get older, especially with things like telomeres and telomerase, which are important for keeping cells healthy.!
- This text reviews how these changes in T-cells relate to health, aging, and diseases, especially cancers linked to short telomeres and telomerase problems.!